3 Stocks That Could Gain Ground: Cardiol Therapeutics (CRDL), Adlai Nortye (ANL), Neurogene (NGNE)

The biotechnology sector continues to attract investor attention as clinical-stage companies advance innovative therapies targeting large unmet medical needs. With regulatory milestones, trial execution, and scientific differentiation shaping market sentiment, emerging healthcare firms remain closely watched for their long-term growth potential and commercialization prospects.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) continues to advance its lead cardiovascular therapy at a time when inflammation-focused treatment strategies are receiving growing attention across the biotech sector. As investors evaluate emerging cardiovascular companies, late-stage clinical execution and differentiated science remain important drivers of long-term valuation potential.

Market Momentum

As of May 22, 2026, CRDL closed at $1.32, up 0.76%, with trading volume of 281,359 shares compared to an average volume of 694,533 shares. The company currently maintains a market capitalization of $152.159M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.32 suggests substantial upside potential tied to future clinical and regulatory milestones.

Late-Stage Development Progress

Cardiol’s Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis remains the company’s primary near-term catalyst. The randomized, double-blind, placebo-controlled study has surpassed 75% patient enrollment and was designed in collaboration with the U.S. Food and Drug Administration following encouraging Phase II discussions.

Clinical Foundation

Earlier clinical findings demonstrated reductions in pericarditis-related pain, inflammation, and recurrence frequency while also showing favorable safety and tolerability outcomes. These results have helped strengthen the clinical rationale supporting CardiolRx™ as a potential treatment option for patients suffering from recurrent inflammatory heart disease.

Outlook

With enrollment continuing to advance and earlier clinical data supporting the therapy’s development profile, Cardiol appears increasingly well-positioned as it moves toward future regulatory discussions and potential commercialization opportunities.

Adlai Nortye Ltd ADR (ANL)

Adlai Nortye Ltd ADR (NASDAQ: ANL) started the day on May 22, 2026, with a price increase of 3.11% at $11.92. During the day, the stock rose to $12.07 and sank to $11.53. Taking a long-term approach, ANL posted a 52-week range of $0.88-$17.25.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 10.50%. Meanwhile, its Annual Earnings per share during the time was 10.50%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 40.54%. This publicly-traded company’s shares outstanding now amount to $34.34 million, simultaneously with a float of $31.12 million. The organization now has a market capitalization of $409.33 million.

Neurogene Inc (NGNE)

As of May 22, 2026, Neurogene Inc (NASDAQ: NGNE) got off with the flyer as it spiked 0.36% to $27.71. During the day, the stock rose to $28.25 and sank to $27.344. Taking a long-term approach, NGNE posted a 52-week range of $14.65-$37.27.

In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -45.84%. Meanwhile, its Annual Earnings per share during the time were -45.84%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -31.47%. This publicly-traded company’s shares outstanding now amount to $15.62 million, simultaneously with a float of $12.53 million. The organization now has a market capitalization sitting at $437.87 million.